Abstracts tagged "skin fibrosis and systemic sclerosis"

Abstract Number: 970 • 2016 ACR/ARHP Annual Meeting
The Serotonin Receptor 2 Inhibitor Terguride Has Beneficial Effects on Skin Fibrosis: Results from a Phase 2 Proof of Concept Study
Oliver Distler¹, Britta Maurer¹, Serena Vettori², Sandra Blumhardt³, Diana Frey⁴, Alfiya Distler⁵, Christian Beyer⁶ and Joerg HW Distler⁷, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ³rheumatology, USZ, zurich, Switzerland, ⁴USZ, Zurich, Switzerland, ⁵Dept Int Med 3, Univ Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Circumstantial evidence from preclinical studies indicates a key role of serotonin (5-HT) signaling via the 5-HT-2B receptor in the development of fibrosis. Terguride is…
Abstract Number: 1850 • 2016 ACR/ARHP Annual Meeting
Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Tomoya Watanabe¹, Tetsuya Nishimoto², Jonathan Heywood³, Stanley Hoffman⁴, Logan Mlakar⁴ and Carol A. Feghali-Bostwick⁵, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Rheumataology, Medical University of South Carolina, Chareston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. Traditionally, daily subcutaneous injections of BLM for 4-6…
Abstract Number: 1873 • 2016 ACR/ARHP Annual Meeting
Longitudinal Analysis of Modified Rodnan Skin Score in Systemic Sclerosis Using Group-Based Trajectory Modelling
Emmanuel Ledoult^1,2, Vincent Sobanski^1,3,4,5, Luc Mouthon^6,7,8, Hélène Béhal⁹, Christian Agard¹⁰, Jean-Christophe Lega¹¹, Patrick Jego¹², Yves-Michel Frances¹³, Gilles Kaplanski^14,15, Jean-Robert Harle¹⁶, Sabine Berthier¹⁷, Boris Bienvenu¹⁸, Olivier Fain¹⁹, Arsene Mekinian²⁰, Elisabeth Diot²¹, Robin Dhote²², Alain Le Quellec²³, Zahir Amoura^24,25, Noemie Le Gouellec²⁶, Jean-Emmanuel Kahn²⁷, Nadine Magy²⁸, Marie-Hélène Balquet²⁹, Grégory Pugnet³⁰, Thomas Papo³¹, Pierre Kieffer³², Viviane Queyrel³³, Jean-Baptiste Gaultier³⁴, Denis Wahl³⁵, Francois Maurier³⁶, Emmanuel Chatelus³⁷, Jean-Louis Pennaforte³⁸, Olivier Aumaître³⁹, Olivier Lidove⁴⁰, Cristina Belizna⁴¹, Carine Boulon⁴², Marie-Elise Truchetet⁴³, Jacques Pouchot⁴⁴, Eric Auxenfants⁴⁵, Anne-Laure Fauchais⁴⁶, Bernard Imbert⁴⁷, Eric Hachulla^1,48,49,50, David Launay^3,4,5,51 and the French Autoimmune and Autoinflammatory Rare Diseases Network (FAI2R), ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, ²CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, ³CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, ⁴Inserm, U995, F-59000 Lille, France, Lille, France, ⁵Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁶Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ⁹Maison Régionale de la Recherche Clinique. CHU de Lille. F- 59000 Lille, France, Lille, France, ¹⁰Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹¹Internal Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France, ¹²CHU de Rennes - Internal Medicine, Rennes, France, ¹³Médecine gériatrique - Hôpital Nord - F-13000 Marseilles, Marseilles, France, ¹⁴Aix-Marseille Université - Internal Medicine hopital conception - F-13000 Marseilles, Marseille, France, ¹⁵INSERM U608, Marseille, France, ¹⁶Service de médecine interne et immunologie clinique / Hôpital de la Timone, Marseilles, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁸Caen University Hospital, Caen, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ²¹Pôle médecine interne et gériatrique, pneumologie CHRU de Tours - Hôpital Bretonneau, Tours, France, ²²Service de médecine interne. Hôpital Avicenne, Paris, France, ²³Division of internal Medicine, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, Montpellier, France, ²⁴Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²⁵Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ²⁶Internal Medicine, Lille, France, ²⁷Internal Medicine, Foch Hospital, Suresnes, France, ²⁸Médecine Interne. CHU Besancon, Besancon, France, ²⁹Médecine Interne - CH Lens, Lens, France, ³⁰Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³¹Bichat University Hospital - Internal Medicine, Paris, France, ³²Hopital Emile Muller - Medecine Interne, Mulhouse Cedex 1, France, ³³Service de médecine interne - CHU de Nice. Hopital de l'Archet., Nice, France, ³⁴Pole de Gériatrie et Médecine interne - CHU Saint-Etienne, Saint-Etienne, France, ³⁵CHU de Nancy - Service de médecine interne - Unité de Médecine vasculaire Institut lorrain du coeur et des vaisseaux Louis Mathieu, Nancy, France, ³⁶Centre de Compétences des Maladies Systémiques Rares - CHU Metz, metz, France, ³⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³⁸Service de médecine interne Pôle Médecines CHU de Reims - Hôpital Robert Debré, Reims, France, ³⁹CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁴⁰Service de Médecine Interne-Rhumatologie Hôpital de la Croix St Simo, Paris, France, ⁴¹Angers University hospital - Internal Medicine, Angers, France, ⁴²Service de médecine interne et vasculaire - CHU Bordeaux, Bordeaux, France, ⁴³CHU de Bordeaux - Service de médecine interne, Bordeaux, France, ⁴⁴Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ⁴⁵CH Roubaix - Médecine interne, Roubaix, France, ⁴⁶Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁴⁷CHU, Grenoble, Grenoble, France, ⁴⁸CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000, France, ⁴⁹Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, ⁵⁰Inserm, U995, F-59000 Lille, France, ⁵¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France
Background/Purpose: The modified Rodnan skin score (mRSS) is a clinical evaluation score of the extent of cutaneous fibrosis in systemic sclerosis (SSc). mRSS has been…
Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Robyn T. Domsic¹, Mary Lucas², Virginia D. Steen³ and Thomas A. Medsger Jr.⁴, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…
Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Rajaie Namas^1,2, Donald P. Tashkin³, Holly Wilhalme⁴, Daniel E. Furst⁵, Chi-hong Tseng⁶, Michael Roth⁶, Suzanne Kafaja⁷, Elizabeth R. Volkmann⁴, Philip J. Clements⁶ and Dinesh Khanna⁸, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵UCLA, Los Angeles, CA, ⁶Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Michigan, Ann Arbor, MI
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…
Abstract Number: 1080 • 2015 ACR/ARHP Annual Meeting
Modified Rodnan Skin Score Thresholds for the Optimization of Cohort Enrichment in Clinical Trials in Skin Fibrosis in Patients with Diffuse Cutaneous Systemic Sclerosis
Rucsandra Dobrota¹, Britta Maurer¹, Nicole Graf², Suzana Jordan³, Carmen Marina Mihai⁴, Otylia Kowal-Bielecka⁵, Yannick Allanore⁶, Oliver Distler¹ and EUSTAR co-authors, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²graf biostatistics, Winterthur, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose: The modified Rodnan skin score (mRSS) is the major outcome measure for skin fibrosis in clinical trials (CT) in diffuse cutaneous scleroderma (dcSSc). Traditionally,…
Abstract Number: 1873 • 2015 ACR/ARHP Annual Meeting
Inter and Intrarater Reliability of the Modified Rodnan Skin Score in Early Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Veronica J. Berrocal², Shervin Assassi³, Elana J. Bernstein⁴, Robyn T. Domsic⁵, Faye N. Hant⁶, Monique E. Hinchcliff⁷, Elena Schiopu⁸, Virginia D. Steen⁹, Tracy M. Frech¹⁰ and Dinesh Khanna¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁸University of Michigan, Ann Arbor, MI, ⁹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: The Modified Rodnan Skin Score (MRSS) is a semiquantitative assessment of skin thickness which is a commonly used outcome measure in Systemic Sclerosis (SSc)…
Abstract Number: 1896 • 2015 ACR/ARHP Annual Meeting
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
WMT van den Hombergh¹, HKA Knaapen-Hans¹, Patricia E. Carreira^2,3, FHJ van den Hoogen¹, Jaap Fransen¹ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Rheumatology Unit, Hospital 12 de Octubre, Hospital 12 de Octubre, Madrid, Spain
ABSTRACT Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with a poorer prognosis compared to limited cutaneous SSc (lcSSc), due to earlier and more severe…
Abstract Number: 1905 • 2015 ACR/ARHP Annual Meeting
Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies
Peter Sandner^1,2, Clara Dees³, Joerg H. W. Distler³, Christian Beyer³, Alfiya Distler³, Yun Zhang⁴, Katrin Palumbo-Zerr⁴, Georg A. Schett⁵, Alina Soare^3,6, Oliver Distler⁷ and Emanuel Haasbach⁸, ¹Bayer Health Care, Global Drug Discovery, Bayer Pharma AG, Wuppertal, Germany, ²Institute of Pharmacology, Hannover Medical School, Hannover, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania, ⁷Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Bayer HealthCare, Bayer Pharma AG, Wuppertal, Germany
Background/Purpose: Systemic sclerosis (SSc) is characterised by fibrosis and vascular alterations, both of which account for the high morbidity and mortality of SSc. Although several…
Abstract Number: 1707 • 2014 ACR/ARHP Annual Meeting
High Oxidative Stress in Fibrotic and Non-Fibrotic Skin of Patients with Systemic Sclerosis
Khalil I. Bourji¹, Alain Meyer^2,3, Emmanuel Chatelus², Erika Pigatto¹, François Singh³, Bernard Geny³, Leonardo Punzi¹, Jacques-Eric Gottenberg², Franco Cozzi¹ and Jean Sibilia², ¹Division of Rheumatology, University Hospital of Padova, Padova, Italy, ²Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ³Physiology and Functional Explorations, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose Systemic Sclerosis (SSc) is a chronic multisystemic connective tissue disease characterized by progressive fibrosis affecting skin and internal organs. Despite serious efforts to unveil…
Abstract Number: 1698 • 2014 ACR/ARHP Annual Meeting
Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity
Tamao Nakashita¹, Shinji Motojima², Katsutoshi Ando³ and Akira Dibatake⁴, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, ²[email protected], Kameda Medical Center, Kamogawa City, Japan, ³Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan, ⁴Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose : Increased levels of serum pro-fibrotic cytokines such as IL-4 and IL-13 and plasma CXCL4 have been previously reported in patients with systemic sclerosis…
Abstract Number: 751 • 2014 ACR/ARHP Annual Meeting
Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis
Shervin Assassi¹, William Swindell², Minghua Wu¹, Filemon K. Tan¹, Dinesh Khanna³, Daniel E. Furst⁴, Donald Tashkin⁵, Richard Jahan-Tigh⁶, Maureen D Mayes¹, Johann Gudjonsson² and Jeffrey T. Chang⁶, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Dermatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴University of California at Los Angeles, Los Angeles, CA, ⁵Medicine, University of California at Los Angeles, Los Angeles, CA, ⁶University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: To examine the heterogeneity of global transcriptome patterns in systemic sclerosis (SSc) skin from a large cohort of patients and controls. Methods: Skin biopsies…
Abstract Number: 722 • 2014 ACR/ARHP Annual Meeting
Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis
Rucsandra Dobrota^1,2, Britta Maurer¹, Nicole Graf³, Carina Mihai², Otylia Kowal-Bielecka⁴, Yannick Allanore⁵ and Oliver Distler on behalf of the EUSTAR investigators and co-authors¹, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³graf biostatistics, Winterthur, Switzerland, ⁴Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁵Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose Improvement of skin fibrosis over time is part of the “natural history” of patients with diffuse cutaneous systemic sclerosis (dcSSc). However, in the individual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].